We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00289159
Recruitment Status : Unknown
Verified September 2005 by Groupe Hospitalier Pitie-Salpetriere.
Recruitment status was:  Active, not recruiting
First Posted : February 9, 2006
Last Update Posted : February 9, 2006
Information provided by:

Study Description
Brief Summary:
To determine wether multimodal MRI (conventinal T1 and T2 sequences, diffusion, magnetization transfer, spectroscopy) is reproducible; to follow up a cohort of patients with early remmittent MS after treatment with interferon.

Condition or disease Phase
Multiple Sclerosis Phase 4

Study Design

Study Type : Observational
Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MS patients according to Poser's criteria
  • Remitting evolution (less than two years of evolution)
  • Aged 18-50
  • Immunomodulatory treatment indicated

Exclusion Criteria:

  • Unable to perform MRI
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00289159

Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France
Principal Investigator: Ayman Tourbah, MD, PhD Assistance Publique - Hôpitaux de Paris
More Information

ClinicalTrials.gov Identifier: NCT00289159     History of Changes
Other Study ID Numbers: RBM0110
First Posted: February 9, 2006    Key Record Dates
Last Update Posted: February 9, 2006
Last Verified: September 2005

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
aged 18-50
remitting evolution
less than two years of evolution
MS patients

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases